Clinical TrialMay 7, 2026, 04:08 PM
Camp4 Therapeutics Files for CMP-002 Clinical Trial in Australia
AI Summary
Camp4 Therapeutics announced significant progress in its clinical development, including the submission of its first regulatory filing for CMP-002 in Australia, with plans to initiate a global Phase 1/2 clinical trial in SYNGAP1 patients in the second half of 2026. The company also received Orphan Designation for CMP-002 from the European Medicines Agency and entered a collaboration with CURE SYNGAP1. Financially, Camp4 reported $99.2 million in cash and cash equivalents as of March 31, 2026, with a cash runway expected into 2028, though its net loss for Q1 2026 increased to $18.3 million.
Key Highlights
- Submitted first regulatory filing for CMP-002 in Australia for global Phase 1/2 clinical trial.
- Anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026.
- Received Orphan Designation for CMP-002 from the European Medicines Agency (EMA).
- Entered collaboration with CURE SYNGAP1 to support ProMMiS natural history study.
- Cash and cash equivalents were $99.2 million as of March 31, 2026.
- Cash runway expected into 2028.
- Q1 2026 R&D expenses were $10.2 million, compared to $10.1 million in Q1 2025.
- Q1 2026 net loss was $18.3 million, compared to $12.4 million in Q1 2025.
Price Impact
More from CAMP